Asciminib for chronic myeloid leukaemia after two or more tyrosine kinase inhibitors

^*Corresponding author for this work

Research output: Book/Report › Commissioned report

Original language	English
Publisher	National Institute for Health and Care Excellence
Commissioning body	National Institute for Health and Care Excellence
Publication status	Published - 3 Aug 2022

Access to Document

@book{8ae936a801be4bf081069c18bb40f0e7,

title = "Asciminib for chronic myeloid leukaemia after two or more tyrosine kinase inhibitors",

author = "Murphy, {Peter James} and Alexis Llewellyn and Nick Meader and Robert Hodgson and Simmonds, {Mark Crawford}",

year = "2022",

month = aug,

day = "3",

language = "English",

publisher = "National Institute for Health and Care Excellence",

}

TY - BOOK

T1 - Asciminib for chronic myeloid leukaemia after two or more tyrosine kinase inhibitors

AU - Murphy, Peter James

AU - Llewellyn, Alexis

AU - Meader, Nick

AU - Hodgson, Robert

AU - Simmonds, Mark Crawford

PY - 2022/8/3

Y1 - 2022/8/3

M3 - Commissioned report

BT - Asciminib for chronic myeloid leukaemia after two or more tyrosine kinase inhibitors

PB - National Institute for Health and Care Excellence

ER -